Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 6/20 | 0.50 |
| ▸ | ICMT | O60725 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | CDC25A | P30304 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041029 | 0.91 | HTR2A (0.62) | HTR2AHTR6ICMTCNR2CDC25A | |
| SCHEMBL3886988 | 0.89 | ICMT (0.64) | HTR2AICMTCNR2CDC25ACNR1 | |
| SCHEMBL12558504 | 0.88 | CNR2 (0.58) | HTR2AHTR6ICMTCNR2CDC25A | |
| SCHEMBL22411431 | 0.88 | ICMT (0.66) | HTR2AICMTCNR2CDC25ACNR1 | |
| SCHEMBL4535061 | 0.87 | HTR2A (0.65) | HTR2AHTR6SCN9AHRH1 | |
| SCHEMBL11375790 | 0.84 | IL6ST (0.53) | HTR6ICMTCNR2CDC25ACNR1 | |
| SCHEMBL8758217 | 0.83 | HTR2A (0.60) | HTR2AHTR6CNR2CNR1SCN9A | |
| SCHEMBL8758275 | 0.83 | HTR6 (0.67) | HTR2AHTR6CNR2 | |
| SCHEMBL27937525 | 0.83 | HTR2A (0.60) | HTR2AHTR6SCN9AHRH1 | |
| SCHEMBL10650270 | 0.83 | CNR2 (0.58) | HTR6ICMTCNR2CDC25ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122474-A1 | 4-HYDROXY-N-PROPYLTRYPTAMINE | CAAMTECH, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4247340-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2022109050-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| WO-2025122474-A1 | 4-HYDROXY-N-PROPYLTRYPTAMINE | CAAMTECH, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250182901-A1 | SYSTEMS AND METHODS FOR AFFECTING WELL-BEING | DIAMOND THERAPEUTICS INC (CA) | 2025-06-05 | — | — | US | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107829-A1 | CRYSTALLINE N-METHYL TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4333838-A1 | FUNGAL COMPOUND COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATION | Turtle Bear Holdings, LLC (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4313007-A1 | TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT | Lyfe CHNG, LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023225113-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4247340-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | Bexson Biomedical, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022109050-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS | BEXSON BIOMEDICAL, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | TURTLE BEAR HOLDINGS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-6255335-B1 | BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-03 | — | — | US | disclosed |
| EP-1071664-A1 | SUBSTITUTED 2-OXO-ALKANOIC ACID- 2-(INDOL-3-YL)-ETHYL] AMIDES | BAYER AG (DE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054301-A1 | SUBSTITUTED 2-OXO-ALKANOIC ACID-[2-(INDOL-3-YL)-ETHYL] AMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | HTR2A 586/4885HTR6 596/4885ICMT 3313/4885 |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2A 34/4885HTR6 12/4885ICMT 376/4885 |
| US-20210145851-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | HTR1B, HTR6, BDNF | HTR2A 11/4885HTR6 2/4885ICMT 2260/4885 |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | HTR2A 586/4885HTR6 596/4885ICMT 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.